NCT05283395 - Rocklatan® Evaluation | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

March 22, 2023

Study Completion Date

March 22, 2023

Conditions

Glaucoma

Interventions

DRUG

Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

Trial Locations (21)

11030

OCLI Vision, Manhasset

16066

Scott & Christie and Associates, PC, Cranberry Township

22046

Emerson Clinical Research Institute, Falls Church

24016

Vistar Eye Center, Roanoke

30076

Coastal Research Associates LLC, Roswell

30342

Georgia Eye Partners, Atlanta

33773

Shettle Eye Research, Largo

34285

Center For Sight, Venice

37072

Advancing Vision Research, Goodlettsville

38120

VRF Eye Specialty Group, Memphis

38199

Total Eye Care, PA, Memphis

53405

The Eye Centers of Racine and Kenosha, Racine

63128

Tekwani Vision Center, St Louis

74104

Mark J. Weiss, MD, Inc., Tulsa

77025

Houston Eye Associates, Houston

78731

Keystone Research, Austin

79902

Louis M. Alpern, M.D., M.P.H., P.A, El Paso

91107

California Eye Specialists Medical Group, Pasadena

91345

North Valley Eye Medical Group, Mission Hills

92663

Visionary Eye Institute, Newport Beach

94954

North Bay Eye Associates, Petaluma